Sisram Medical has restructured its DAXXIFY (prabotulinumtoxinA) distribution agreement in China, now involving a connected Fosun unit. DAXXIFY, a long-acting botulinum toxin approved in the U.S. and EU, represents a competitive challenge to Botox and Dysport in markets where practitioners seek extended duration and reduced re-treatment frequency.
Business & M&A
Sisram Medical Restructures DAXXIFY China Deal With Fosun — Botulinum Toxin Strategy Shifts
Aesthetic device company revamps toxin distribution partnership; signals market complexity in China toxin licensing.
Sisram restructures DAXXIFY China deal with Fosun unit amid toxin market complexity.
The deal restructuring suggests Sisram is optimizing its China go-to-market strategy amid regulatory complexity and competitive pressure from AbbVie and Galderma. For U.S. medspa owners, DAXXIFY's presence in international markets signals the toxin category's ongoing fragmentation and the potential for duration-based differentiation to drive adoption if reimbursement and pricing align. Sisram's pivot underscores the importance of local partnerships in regulated aesthetics markets.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.